Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis

Overview of attention for article published in Targeted Oncology, February 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 42 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 7,866 followers.

RT @biogemfinder: $EXEL $IBB $SPY $XBI Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell…

30 Oct 2018

Reply Repost Favourite

$EXEL $IBB $SPY $XBI Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis https://t.co/WGTwoZ7YZs

30 Oct 2018

Reply Repost Favourite

RT @TargetOncology: Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatm…

20 Mar 2018

Reply Repost Favourite

RT @TargetOncology: Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatm…

11 Mar 2018

Reply Repost Favourite

Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis https://t.co/2AvW7tiTyO

01 Mar 2018

Reply Repost Favourite